Vesicular stomatitis virus: an exciting new therapeutic oncolytic virus candidate for cancer or just another chapter from Field's Virology?

Cancer Cell. 2003 Oct;4(4):241-3. doi: 10.1016/s1535-6108(03)00251-4.

Abstract

Selected mutant strains of vesicular stomatitis virus (VSV) are described that are unable to combat endogenous IFN-beta signaling within infected normal cells and as a result are dramatically more selective for productive growth in tumor cells having a defective antiviral response. The VSV mutants may have the potential to be used clinically as a systemic oncolytic agent for the treatment of distal and metastatic cancers.

Publication types

  • Review

MeSH terms

  • Animals
  • Humans
  • Interferon-beta / antagonists & inhibitors
  • Interferon-beta / metabolism*
  • Mutation
  • Neoplasms / therapy
  • Neoplasms / virology
  • RNA Virus Infections / therapy*
  • RNA Virus Infections / virology
  • Signal Transduction
  • Vesicular stomatitis Indiana virus / physiology*
  • Viruses / metabolism*

Substances

  • Interferon-beta